Citations

Clear

350 citation(s) found for "Stevens, V".

Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
Gauckler, Philipp , Fernández‐Juárez, Gema , Floege, Jürgen , Frangou, Eleni , Goumenos, Dimitrios, Kronbichler, Andreas , Fernández-Juárez, Gema , Moura, Marta Casal , Anders, Hans‐Joachim , Bruchfeld, Annette N. , Segelmark, Mårten , Türkmen, Kültiğin , Kooten, Cees van , Tesař, Vladimı́r , Geetha, Duvuru , Fervenza, Fernando C. , Jayne, David , Stevens, Kate

Mayo Clinic

Nephrology Dialysis Transplantation | May 11, 2023 | Volume: 38 | Issue: 11 | Pages: 2637-2651

10.1093/ndt/gfad090 | PMID 37164940 Get It

ABSTRACT Updated guidelines on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) were released in 2021 by the American College of Rheumatology jointly with the Vasculitis Foundation and, subsequently, in 2022 by the European Alliance of Associations for Rheumatology. In addition, in 2021, the Kidney Disease: Improving Global Outcomes had released updated recommendations on the treatment of AAV with glomerulonephritis (AAV-GN). Kidney involvement is particularly relevant in microscopic polyangiitis and granulomatosis with polyangiitis, but is less frequent in eosinophilic granulomatosis with polyangiitis. The management of AAV-GN has been a focus for drug development and change over the past 10 years. Avoidance of progression to end-stage kidney disease (ESKD) or kidney failure is one of the main unmet needs in the management of AAV, with ESKD having a major impact on morbidity, health costs and mortality risk. Relevant changes in AAV-GN management are related to remission-induction treatment of patients with severe kidney disease, the use of glucocorticoids and avacopan, and remission-maintenance treatment. All the documents provide guidance in accordance with the evidence-based standard of care available at the time of their release. With our work we aim to (i) show the progress made and identify the differences between guidelines and recommendations, (ii) discuss the supporting rationale for those, and (iii) identify gaps in knowledge that could benefit from additional research and should be revised in subsequent updates.
Papanicolaou test collection with the Papette brush or the spatula with cytobrush: A pragmatic study
O’Laughlin, Danielle , Strelow, Brittany , Fellows, Nicole, Stevens, Joy , Kelsey, Elizabeth A. , Fink, Stephanie, Peters, Sonya, Johnson, Jennifer, Houghton, Jaclyn P, Stolp, Anne, Tweedy, Johanna, DeJesus, Ramona S. , O'Laughlin, Danielle J , Strelow, Brittany A , Fellows, Nicole A, Stevens, Joy N, Fink, Stephanie R, Peters, Sonya M, Johnson, Jennifer A, Stolp, Anne M, Tweedy, Johanna M, DeJesus, R S , Fischer, Karen M.

Mayo Clinic

Women's Health | April 29, 2023 | Volume: 19 | Issue: No issue available | Pages: No page available

10.1177/17455057231170975 | PMID 37119034 Get It

Background: Cotesting with the Papanicolaou (Pap) and human papillomavirus tests detects most precancerous and cancerous lesions and increases the sensitivity for detecting high-grade precancerous and invasive cervical cancers compared with human papillomavirus testing alone. Objective: To compare the use of the Papette brush (hereafter Papette) to the traditional spatula with endocervical brush (cytobrush) for cervical cancer screening. Design: Pragmatic observational study. Methods: Adult women aged 21–64 years who were eligible for a Papanicolaou test at a Midwest Community Internal Medicine practice underwent cervical cancer screening using the Papette or spatula with cytobrush from 18 August 2021 through 1 February 2022. Cluster sampling was used across the practice. Pathology reports were then analyzed to compare the number of satisfactory versus unsatisfactory results between the two collection techniques. Results: We collected results for 756 Pap tests. The test results were satisfactory with the Papette 93.8% of the time compared with 93.0% for the spatula with cytobrush. Conclusion: The Papette is not inferior to a spatula with cytobrush as a collection method for Pap tests.
A Broad Spectrum of Possibilities: Spectrum Scores as a Unifying Metric of Antibiotic Utilization
Ilges, Dan , Ilges, Dan , Tande, Aaron J. , Stevens, Ryan W.

Mayo Clinic

Clinical Infectious Diseases | March 31, 2023 | Volume: 77 | Issue: 2 | Pages: 167-173

10.1093/cid/ciad189 | PMID 36999909 Get It

Abstract Days of therapy (DOT) currently serve as the standard antimicrobial utilization metric. However, by assigning the same weight to each agent rather than accounting for differences in spectrum of activity, DOT ignore key differences between agents that are fundamental to infectious diseases and critical to antimicrobial stewardship. Spectrum scoring assigns numeric values to individual antibiotic agents to quantify their spectrum of activity, allowing for the normalization of antibiotic utilization data. When used in conjunction with traditional metrics, spectrum scores may offer further clarity to antibiotic utilization; however, issues related to development, application, and standardization of spectrum scores remain. Despite these challenges, the potential applications of spectrum scores are vast. Here, we summarize existing data and explore the future of spectrum scoring, including application to both data analysis and routine patient care, use in inpatient and outpatient settings, integration within the electronic medical record, and opportunities for future research.
Retrospective Evaluation of the Association of Oxacillin MIC on Acute Treatment Outcomes with Cefazolin and Antistaphylococcal Penicillins in Methicillin-Susceptible Staphylococcus aureus Bacteremia
Hess, Kyle A., Kooda, Kirstin , Shulha, Jennifer A., Mara, Kristin C. , Mara, Kristin, Go, John R, Mara, Kristin C , Shulha, Jenny , Go, John Raymond , Fida, Madiha , DeSimone, Daniel C. , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | March 29, 2023 | Volume: 61 | Issue: 4 | Pages: No page available

10.1128/jcm.00039-23 | PMID 36988505 Get It

Antistaphylococcal penicillins (ASP) and cefazolin are first-line treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Borderline oxacillin resistance (i.e., oxacillin MICs 1-8 μg/mL) is observed in strains hyperproducing beta-lactamases.
Structure-based design and characterization of Parkin-activating mutations
Stevens, Michael , Croteau, Nathalie , Eldeeb, Mohamed A. , Zeng, Zhi Wei , Toth, Rachel , Durcan, Thomas M. , Springer, Wolfdieter , Muqit, Miratul M. K. , Trempe, Jean‐François , Toth, Rachel , Springer, Wolfdieter , Fon, Edward A , Muqit, Miratul Mk , Trempe, Jean-François , Antico, Odetta

Mayo Clinic

Life Science Alliance | March 20, 2023 | Volume: 6 | Issue: 6 | Pages: e202201419

10.26508/lsa.202201419 | PMID 36941054 Get It

Autosomal recessive mutations in the Parkin gene cause Parkinson’s disease. Parkin encodes an ubiquitin E3 ligase that functions together with the kinase PINK1 in a mitochondrial quality control pathway. Parkin exists in an inactive conformation mediated by autoinhibitory domain interfaces. Thus, Parkin has become a target for the development of therapeutics that activate its ligase activity. Yet, the extent to which different regions of Parkin can be targeted for activation remained unknown. Here, we have used a rational structure-based approach to design new activating mutations in both human and rat Parkin across interdomain interfaces. Out of 31 mutations tested, we identified 11 activating mutations that all cluster near the RING0:RING2 or REP:RING1 interfaces. The activity of these mutants correlates with reduced thermal stability. Furthermore, three mutations V393D, A401D, and W403A rescue a Parkin S65A mutant, defective in mitophagy, in cell-based studies. Overall our data extend previous analysis of Parkin activation mutants and suggests that small molecules that would mimic RING0:RING2 or REP:RING1 destabilisation offer therapeutic potential for Parkinson’s disease patients harbouring select Parkin mutations.
Determinants of Professional Fulfillment and Burnout Among Intensivists: A National Survey by the Society of Critical Care Anesthesiologists in 2022
Siddiqui, Shahla , Monteith, Erika, Shaefi, Shahzad , Tung, Avery , Sladen, Robert N. , Warner, Matthew A. , Kelly, Lauren, Douin, David J. , Mladinov, Domagoj , Stevens, Robert David , Siddiqui, Shahla

Mayo Clinic

Anesthesia & Analgesia | February 15, 2023 | Volume: 137 | Issue: 2 | Pages: 375-382

10.1213/ane.0000000000006384 | PMID 36791019 Get It

BACKGROUND: Increased burnout and decreased professional fulfillment among intensive care physicians is partly due to intensive care unit (ICU) workload. Although the SARS-CoV-2 (COVID-19) pandemic increased ICU workload, it also may have increased feelings of personal fulfillment due to positive public perceptions of physicians caring for COVID patients. We surveyed critical care anesthesiologists to identify the effect of provider demographics, ICU workload, and COVID-19–related workload, on professional fulfillment and burnout. METHODS: We performed an exploratory survey of 606 members of the Society of Critical Care Anesthesiologists (SOCCA) in January and February 2022. We used the Stanford Professional Fulfillment Index (PFI) to grade levels of professional fulfillment and markers of burnout (ie, work exhaustion and disengagement). Univariable and multivariable models were used to identify associations between provider demographics and practice characteristics and professional fulfillment and work exhaustion. RESULTS: One hundred and seventy-five intensivists (29%) responded. A total of 65% were male and 49% were between 36 and 45 years old. The overall median PFI score—0 (none) to 24 (most professional fulfillment)—was 17 (IQR, 1–24), with a wide distribution of responses. In multivariable analysis, factors associated with higher professional fulfillment included age >45 years ( P =.004), ≤15 weeks full-time ICU coverage in 2020 ( P =.02), role as medical director ( P =.01), and nighttime home call with supervision of in-house ICU fellows ( P =.01). CONCLUSIONS: Professional fulfillment and work exhaustion in this cross-sectional survey were associated with several demographic and practice characteristics but not COVID-19–related workload, suggesting that COVID-19 workload may not have either positive or negative perceptions on professional fulfillment.
Leptotrichia Bacteremia: 10-Year Retrospective Clinical Analysis and Antimicrobial Susceptibility Profiles
Ranganath, Nischal , Shirley, Joshua D. , Kind, Dalton R., Comba, Işın Y. , Patel, Robin , Schuetz, Audrey N. , Shah, Aditya , Challener, Douglas W. , Comba, Isin Y , Patel, Robin , Schuetz, Audrey N , Shah, Aditya S , Ranganath, Nischal , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | January 30, 2023 | Volume: 61 | Issue: 2 | Pages: No page available

10.1128/jcm.01733-22 | PMID 36715514 Get It

Leptotrichia species are anaerobic, Gram-negative bacilli increasingly recognized as pathogens capable of causing invasive infections such as bloodstream infection (BSI), particularly among immunocompromised patients. However, there is a paucity of data regarding epidemiology, antimicrobial susceptibility, optimal treatment, and clinical outcomes among patients with Leptotrichia bacteremia.
Racial and ethnic disparities in emergency department–initiated buprenorphine across five health care systems
Holland, Wesley C., Jeffery, Molly M. , Stevens, Maria , Melnick, Edward R. , Dziura, James , Khidir, Hazar , Skains, Rachel M. , D’Onofrio, Gail , Soares, William E. , Jeffery, Molly Moore , Melnick, Edward R , Skains, Rachel M , Soares, William E , Li, Fangyong , Nath, Bidisha

Mayo Clinic

Academic Emergency Medicine | January 20, 2023 | Volume: 30 | Issue: 7 | Pages: 709-720

10.1111/acem.14668 | PMID 36660800 Get It

AbstractBackgroundOpioid overdose deaths have disproportionately impacted Black and Hispanic populations, in part due to disparities in treatment access. Emergency departments (EDs) serve as a resource for patients with opioid use disorder (OUD), many of whom have difficulty accessing outpatient addiction programs. However, inequities in ED treatment for OUD remain poorly understood.MethodsThis secondary analysis examined racial and ethnic differences in buprenorphine access using data from EMBED, a study of 21 EDs across five health care systems evaluating a clinical decision support system for initiating ED buprenorphine. The primary outcome was receipt of buprenorphine, ED administered or prescribed. Hospital type (academic vs. community) was evaluated as an effect modifier. Hierarchical models with cluster effects for site and clinician were used to assess buprenorphine receipt by race and ethnicity.ResultsBlack patients were less likely to receive buprenorphine (6.4% [51/801] vs. White patients 8.5% [268/3154], odds ratio [OR] 0.59, 95% confidence interval [CI] 0.45–0.78). This association persisted after adjusting for age, insurance, gender, clinician X‐waiver, hospital type, and urbanicity (adjusted OR [aOR] 0.64, 95% CI 0.48–0.84) but not when discharge diagnosis was included (aOR 0.75, 95% CI 0.56–1.02). Hispanic patients were more likely to receive buprenorphine (14.8% [122/822] vs. non‐Hispanic patients, 11.6% [475/4098]) in unadjusted (OR 1.57, 95% CI 1.09–1.83) and adjusted models (aOR 1.41, 95% CI 1.08–1.83) but not including discharge diagnosis (aOR 1.32, 95% CI 0.99–1.77). Odds of buprenorphine were similar in academic and community EDs by race (interaction p = 0.97) and ethnicity (interaction p = 0.64).ConclusionsBlack patients with OUD were less likely to receive buprenorphine whereas Hispanic patients were more likely to receive buprenorphine in academic and community EDs. Differences were attenuated with discharge diagnosis, as fewer Black and non‐Hispanic patients were diagnosed with opioid withdrawal. Barriers to medication treatment are heterogenous among patients with OUD; research must continue to address the multiple drivers of health inequities at the patient, clinician, and community level.
Does metabolite matter? Defining target itraconazole and hydroxy‐itraconazole serum concentrations for blastomycosis
Firkus, Danielle , Saleh, Omar Abu , Enzler, Mark J., Jannetto, Paul J. , Mara, Kristin C. , Vergidis, Paschalis , Rivera, Christina G. , Stevens, Ryan W. , Abu Saleh, Omar M, Mara, Kristin C , Vergidis, Paschalis , Rivera, Christina G , Stevens, Ryan W

Mayo Clinic

Mycoses | January 17, 2023 | Volume: 66 | Issue: 5 | Pages: 412-419

10.1111/myc.13565 | PMID 36648362 Get It

AbstractBackgroundItraconazole is the recommended first‐line treatment for mild‐to‐moderate blastomycosis and consolidation treatment of moderate‐to‐severe disease. Itraconazole is metabolised into three metabolites, including an active metabolite hydroxy‐itraconazole. Literature provides little evidence indicating whether therapeutic drug monitoring targets should be based on itraconazole parent compound alone or a sum of itraconazole and hydroxy‐itraconazole serum concentrations.ObjectivesThis study aims to compare clinical outcomes and adverse drug events (ADEs) of combined itraconazole and hydroxy‐itraconazole concentrations versus itraconazole parent compound alone in patients with blastomycosis.Patients/MethodsThis study was a retrospective cohort review of patients ≥18 years with probable or proven Blastomyces infection who received itraconazole with at least one documented serum itraconazole concentration. The primary outcome was rate of partial or complete treatment response across three patient groups: (1) Itraconazole parent compound >1.0 mcg/ml (parent), (2) parent compound <1.0 mcg/ml, but a combined itraconazole and hydroxy‐itraconazole >1.0 mcg/ml (combined) and (3) failure to achieve a combined or parent concentration >1.0 mcg/ml (subtherapeutic) for >75% of the duration of itraconazole therapy.ResultsA total of 80 patients were included (parent = 32, combined = 36, subtherapeutic = 12). No statistically significant difference was observed for rate of partial or complete treatment response (97% parent vs 94% combined, p = .99). Significantly higher mortality due to blastomycosis was observed in patients in the subtherapeutic group (0% parent vs 3% combined vs 25% subtherapeutic, p = .01).ConclusionsThis study supports an itraconazole therapeutic target combining itraconazole and hydroxy‐itraconazole >1.0 mcg/ml for blastomycosis treatment.
Increasing Racial and Ethnic Equity, Diversity, and Inclusion in Cancer Treatment Trials: Evaluation of an ASCO-Association of Community Cancer Centers Site Self-Assessment
Guerra, Carmen E. , Pressman, Alice , Hurley, Patricia A. , Garrett‐Mayer, Elizabeth , Bruinooge, Suanna S. , Howson, A. G. , Kaltenbaugh, Melinda , Williams, Jen Hanley, Boehmer, Leigh , Bernick, Lea Ann, Byatt, Leslie, Crews, Jennie R. , McCaskill‐Stevens, Worta , Merrill, Janette K. , Nowakowski, Greg, Patel, Manali I. , Zwicker, Victoria, Oyer, Randall A. , Pierce, Lori J. , Guerra, Carmen E , Hurley, Patricia , Howson, Alexandra , Hanley Williams, Jen , Charlot, Marjory , Merrill, Janette , Nowakowski, Grzegorz S , Patel, Manali I , Ramirez, Amelie G , Oyer, Randall A , Bruinooge, Suanna Steeby , Garrett-Mayer, Elizabeth , Charlot, Marjory , Fashoyin-Aje, Lola

Mayo Clinic

JCO Oncology Practice | January 11, 2023 | Volume: 19 | Issue: 4 | Pages: e581-e588

10.1200/op.22.00560 | PMID 36630663 Get It

Clinical trial participants do not reflect the racial and ethnic diversity of people with cancer. ASCO and the Association of Community Cancer Centers collaborated on a quality improvement study to enhance racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The groups conducted a pilot study to examine the feasibility, utility, and face validity of a two-part clinical trial site self-assessment to enable diverse types of research sites in the United States to (1) review internal data to assess racial and ethnic disparities in screening and enrollment and (2) review their policies, programs, procedures to identify opportunities and strategies to improve EDI. Overall, 81% of 62 participating sites were satisfied with the assessment; 82% identified opportunities for improvement; and 63% identified specific strategies and 74% thought the assessment had potential to help their site increase EDI. The assessment increased awareness about performance (82%) and helped identify specific strategies (63%) to increase EDI in trials. Although most sites (65%) were able to provide some data on the number of patients that consented, only two sites were able to provide all requested trial screening, offering, and enrollment data by race and ethnicity. Documenting and evaluating such data are critical steps toward improving EDI and are key to identifying and addressing disparities more broadly. ASCO and Association of Community Cancer Centers will partner with sites to better understand their processes and the feasibility of collecting screening, offering, and enrollment data in systematic and automated ways.